Abstract. MAPK-activating death domain protein (MADD) binds to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor and acts as a key downstream mediator in the TRAIL-induced apoptosis pathway. The aim of this study was to evaluate the expression of MADD in normal human and adenocarcinoma tissues of the lungs and its influence on proliferation and apoptosis of A549 human lung adenocarcinoma cells. Immunohistochemistry was carried out to detect the expression of MADD in normal and tumor tissues of the lungs. Expression of the MADD gene in A549 cells was measured by reverse transcription-polymerase chain reaction. A549 cells were transfected with plasmids carrying the DNA fragment encoding MADD and lentiviral vectors used for RNA interference, respectively. MADD expression in the transfected A549 cells was determined by western blotting. Proliferation and apoptosis were detected using MTT assay and flow cytometry, respectively. It was found that non-small cell lung cancer tissues expressed MADD at higher levels compared to normal lung tissues, and the level of MADD in lung adenocarcinoma was higher compared to that in lung squamous cell carcinoma. MADD was expressed in A549 cells. Both introduction of the DNA fragment encoding MADD and RNA interference targeting MADD effectively altered levels of MADD in the A549 cells. Overexpression of MADD in the A549 cells inhibited apoptosis and increased survival whereas abrogation of MADD promoted apoptosis and reduced cell proliferation. These results suggest that MADD may be a potential therapeutic target for lung adenocarcinoma therapy involving the TRAIL-induced apoptosis pathway.
Introduction
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), one member of the tumor necrosis factor (TNF) superfamily, binds to its death receptors or decoy receptors on the cell surface in the form of homotrimers and triggers TRAIL-induced apoptosis or inhibits the apoptotic pathway (1) . Once TRAIL binds to its death receptors (DR4 and DR5), FAS-associated protein with death domain (FADD) and caspase-8 or caspase-10 are recruited to death domain motifs of the receptors, and the death-inducing signal complex (DISC) is formed, which eventually allows spontaneous cell apoptosis (2) . In recent years, TRAIL and its receptors have been considered as promising targets for cancer therapy, and several molecular drugs targeting the TRAILinduced apoptosis pathway are already in clinical use (3) .
The MAPK-activating death domain protein (MADD) is encoded by an mRNA formed through the post-transcriptional splicing of exons 16, 21 and 26 of the insulinoma-glucagonoma clone 20 (IG20) gene (4) . It is a 183-kDa protein containing 1647 amino acids and can be phosphorylated by protein kinase B (Akt), a serine/threonine protein kinase, at three highly conserved amino acid sites: S70, T173 and T1041 (5) . MADD is expressed at a low level in normal cells, a relatively higher level in the fetal brain and kidney as well as adult testis, ovarian, brain and heart tissues, and a markedly elevated level in malignant tumors of the pancreas, ovary, kidney, lung and breast (6, 7) . After TRAIL treatment, endogenous MADD binds to the TRAIL death receptor DR4/DR5 cytoplasmic tail by its C-terminal death domain and prevents cell apoptosis by inhibiting caspase-8 activation (8) . Overexpression of MADD enhances TNF-α-induced activation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinase, which eventually contributes to cancer cell survival (9, 10) . Obviously, MADD is a key downstream mediator in the TRAIL-induced apoptosis pathway and plays important roles in enhancing cell proliferation and reducing cell apoptosis.
Lung cancer, the primary malignant tumor of the lungs, is one of the leading causes of cancer-related death. It originates from the bronchial mucosa and is histologically divided into non-small cell lung cancer (NSCLC, approximately 75-80% of lung cancer cases) and small-cell lung cancer (less than 20% of lung cancer cases Paraffin sections were baked at 60˚C for 30 min, de-paraffinized in xylene, and hydrated in descending concentrations of alcohol. Endogenous peroxidase activity was blocked with 0.3% (v/v) hydrogen peroxide in methanol for 30 min. Antigen retrieval was carried out by heating in a microwave oven with 0.01 M citrate buffer, pH 6.0, for 10 min. The sections were then incubated with 5% bovine serum albumin for 30 min at room temperature and subsequently with rabbit anti-MADD primary antibody (provided by Dr B.S. Prabhakar and Dr L.C. Li of the Department of Neurology at Illinois University School of Medicine) at 4˚C overnight in a humidified container. Equal volumes of phosphate-buffered saline (PBS, pH 7.4) and rabbit serum were added instead of the primary antibody as blank and negative controls, respectively. The sections were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (Beijing Zhongshan Golden Bridge Biological Technology Co., Ltd., Beijing, China) at 37˚C for 30 min and stained using a DAB detection kit (Beijing Zhongshan Golden Bridge Biological Technology Co., Ltd.) followed by hematoxylin counterstain and differentiation in HCl-alcohol. After dehydration, the gum mounted sections were photographed under an inverted microscope (BX51 TRF, Olympus, Japan). The integrated optic density (IOD) of the positive area in each microphotograph was assessed using immunohistochemical analysis software (Image-Pro Plus 6.0).
Materials and methods

Immunohistochemistry (IHC
Cell culture. The human lung adenocarcinoma A549 cell line and the human embryonic kidney (HEK) 293T cell line were purchased from the China Center for Type Culture Collection (CCTCC, Shanghai, China). The A549 and HEK293T cells were separately cultured in Ham's F12 medium (Thermo Fisher Scientific Inc., Rockford, IL, USA) and DMEM (high glucose) (Hyclone, Logan, UT, USA), both of which contained 10% fetal bovine serum (FBS, Hyclone), 100 U/ml penicillin and 100 µg/ml streptomycin, at 37°C in a humidified atmosphere with 5% CO 2 . At 80-90% confluence, the cells were subcultured at a ratio of 1:3 with 0.25% trypsin.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was extracted from A549 cells using TRIzol reagent (DBI, Biosciences, USA). Reverse transcription was carried out with 1 µg of total RNA using a ReverTra Ace qPCR RT kit (Toyobo, Osaka, Japan). Briefly, RNA and random primers in a 12-µl reaction mixture were put on ice immediately after incubation at 65˚C for 5 min. Then, cDNAs were synthesized in a 20-µl reaction mixture containing ReverTra Ace, dNTP mix, and RNase inhibitor at 30˚C for 10 min followed by 42˚C for 60 min, 90˚C for 5 min, and 4˚C for 5 min. For PCR amplification, 2 µl of cDNA was added to a 50-µl reaction mixture containing 25 µl 2X Taq PCR Master mix (DBI, Bioscience, USA) and 0.01 µM of each primer. The reaction mixture was first incubated at 50˚C for 30 min and 94˚C for 2 min. Subsequently, 30 cycles of PCR (denaturation at 94˚C for 30 sec, annealing at 55˚C for 30 sec, and extension at 72˚C for 1 min) were carried out with a final incubation at 72˚C for 7 min. Two primer sets, F1/R1 (5'-CGG GACTCTGACTCCGAACCTAC-3' and 5'-GCGGTTCAG CTTGCTCAGGAC-3') and F2/R2 (5'-CTGCAGGTGACCC TGGAAGGGATC-3' and 5'-TGTACCCGGGTCAGCTAG AGACAGGCC-3') were separately used to amplify the desired fragments of the IG20 gene as previously reported (4) . The primers (F/R) for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were provided in the ReverTra Ace qPCR RT kit. PCR products were separated on a 5% polyacrylamide gel. The gel was stained with ethidium bromide and photographed under a UV transilluminator (Alpha Imager™ 2200, San Leandro, CA, USA).
Plasmid transfection. A549 cells were seeded into 6-well plates at a density of 2x10 5 cells/well and cultured in 2 ml Ham's F-12 medium containing 10% FBS without antibiotics for 24 h in a CO 2 incubator. Lipofectamine 2000 (10 µl) (Invitrogen, Carlsbad, CA, USA) and 4 µg pEYFP or pEYFP-MADD plasmid DNA (provided by Prabhakar and Li as previously noted) were separately diluted in 250 µl portions of Opti-MEM reduced serum medium (Invitrogen). After 5 min of incubation at room temperature, the diluted Lipofectamine 2000 and plasmid DNA were mixed together. The DNA-liposome complex was incubated for 20 min at room temperature and then directly added to the cultured cells in 2 ml of Opti-MEM medium. The culture medium was replaced with Ham's F-12 medium containing 10% FBS without antibiotics after transfection for 6 h in the CO 2 incubator. Expression of MADD in the transfected cells was detected using western blot assay after 48 h of incubation.
Lentiviral vector transfection. HEK293T cells were seeded in 100-mm plates at a density of 1.5x10 6 cells/plate and cultured for 24 h. Lentiviruses were produced by co-transfecting 16 µg pNL-SIN-GFP-SCR or pNL-SIN-GFP-MID lentiviral vectors (provided by Prabhakar and Li as previously noted) and 32 µl Lenti-Pac HIV Mix (GeneCopoeia, Rockville, MD, USA) into HEK293T cells. The medium was replaced with fresh medium after transfection for 16 h. The lentiviruscontaining supernatant was harvested after incubation for 40 h and filtered using a 0.45-µm filter. The optimal viral titer was determined by transfecting HEK293T cells using a previously described method (11) . A549 cells were seeded in 6-well plates at a density of 5x10 5 cells/well and cultured in 2-ml complete medium. After incubation for 24 h, the medium was replaced with serum-free medium containing 8 µg/ml Polybrene (Sigma, St. Louis, MO, USA), and the viral supernatant was added to the cells in multiples of infection of 10. After 6 h of incubation for transfection, the medium was replaced with complete medium, the cells were incubated for a further 48 h, and expression of MADD in the transfected cells was detected using western blot assay.
Protein determination and western blot analysis. The transfected cells were lysed with RIPA lysis buffer (Thermo Fisher Scientific Inc.). After centrifugation at 13,000 x g for 20 min at 4˚C, protein concentrations in the cell lysates were determined using a BCA protein assay kit (Beyotime, Jiangsu, China). Samples corresponding to 20 µg of protein were fractionated by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. The membrane was blocked with TBST buffer (20 mM Tris-buffered saline with 0.1% Tween-20) containing 5% non-fat dry milk for 1 h at room temperature and incubated with primary antibodies targeting β-actin (Beijing Zhongshan Golden Bridge Biological Technology Co., Ltd.) and MADD at 4˚C overnight. The next day, the membrane was washed 3 times for 5 min each time with TBST buffer and incubated with HRP-conjugated secondary antibody at room temperature for 1 h. After the membrane was washed once with TBS (20 mM Tris-buffered saline) for 15 min and twice with TBST for 5 min each at room temperature, MADD and β-actin on the membrane were detected using Pierce ECL Western blotting substrate (Thermo Fisher Scientific Inc.) by a chemiluminescence apparatus (FluorChemÂ ® Q, Cell Biosciences, Santa Clara, CA, USA).
MTT assay. A549 cells were seeded into 96-well plates at a density of 5x10 3 cells/well (for plasmid transfection) or 1x10 Statistical analysis. All of the experiments were conducted at least three times. Data are shown as the means ± SD. Statistical significance was determined by statistical analysis software SPSS 17.0. P<0.05 was considered to indicate a statistically significant result.
Results
Expression of MADD in normal lung tissues and NSCLC.
In this study, the clinicopathological features of 68 samples of tissues of the lungs were analyzed. These included 20 samples of normal tissues, 31 samples of SCC tissues and 17 samples of ADC tissues. There was no significant difference in gender and age among the three groups. Clinicopathological characteristics of the tumor tissues are summarized in Table I . IHC results are shown in Fig. 1 and Table II . MADD was expressed in both normal lung and NSCLC tissues. IOD analysis revealed that the expression level of MADD in ADC or SCC was higher than that in the normal lung tissues (P<0.01). The mean IOD values of the ADC and SCC tissues were 1.95 and 1.61 times that of normal lung tissues, respectively. It was also found that ADC expressed more MADD than SCC (P<0.01). The mean IOD of ADC tissues was 1.22 times that of SCC tissues. In addition, IOD analysis showed that levels of MADD expression in both the ADC and SCC tissues were not related to differentiation and stage of ADC and SCC.
Expression of the IG20 gene in A549 cells. As MADD was expressed at a relatively higher level in ADC, all subsequent studies were carried out using the human lung adenocarcinoma cell line A549. First, RT-PCR assay was applied to examine mRNA expression of the IG20 gene in A549 cells since MADD is a splice variant of IG20. RT-PCR results are shown in Fig. 2 . Four spliced transcripts, ~1 kb in length, were amplified with the primer pair F1 and R1 that targets exons 13L and 16 of the IG20 gene (Fig. 2, lane 4) . These are the transcripts encoding IG20pa, MADD, IG20-SV2 and DENN-SV. With the primer pair F2 and R2 targeting exon 34 of the IG20 gene, only one fragment of ~300 bp was amplified (Fig. 2, lane 2) , which means that the transcripts encoding KIAA0358 and IG20-SV4 were undetectable in A549 cells. These results indicated that the four splice variants of IG20, which included MADD, were expressed in A549 cells. whereas it was markedly decreased in the A549 cells subjected to RNAi targeting of MADD (P<0.01 vs. control, Fig. 3B and  D) ; both introduction of the exogenous MADD gene and RNAi targeting of MADD effectively altered the MADD expression levels in A549 cells.
Effects of MADD on A549 cell proliferation.
MTT assay was performed to observe the effects of MADD on the proliferation of A549 cells. As showed in Fig. 4 , the A549 cells transfected with the pEYFP-MADD plasmids, in which MADD was overexpressed, demonstrated greater viability than the control cells (P<0.01, Fig. 4A ) while the viability of the A549 cells transfected with the pNL-SIN-GFP-MID lentiviral vectors, with silenced expression of MADD, was lower than that of the control cells (P<0.01, Fig. 4B ). Obviously, MADD promotes proliferation of A549 cells.
Effects of MADD on the apoptosis of A549 cells.
To further investigate the mechanisms by which MADD promotes proliferation of A549 cells, FCM was utilized to evaluate the apoptosis of A549 cells. FCM results are shown in Table III and Fig. 5 . The apoptosis rate of control cells was 2.4±0.5%. The apoptosis rate of the A549 cells transfected with the pEYFP-MADD plasmids decreased to 1.4±0.6%, whereas that of the A549 cells transfected with the pNL-SIN-GFP-MID lentiviral vectors increased to 6.7±1.5%. These results demonstrated that overexpression of MADD effectively inhibits A549 cell apoptosis, and down-modulation of MADD obviously enhances apoptosis, which suggests that in A549 cells, MADD distinctly affects apoptosis and functions as an inhibitor of apoptosis. 
Discussion
The worldwide incidence of lung cancer has rapidly increased in recent years. The exact pathogenesis of lung cancer is still unclear. Studies have revealed that the development of lung cancer is closely associated with abnormal alterations in oncogenes, tumor-suppressor genes, cytokines and their receptors and cell adhesion molecules (12) (13) (14) . For early-stage lung cancer without overt metastasis, surgery is the optimal choice while it has great limitations for advanced-stage or metastatic lung cancer. However, the fact is that most patients with lung cancer are diagnosed with advanced-stage disease or metastasis. Although radiotherapy and chemotherapy are also feasible therapies for lung cancer, severe side effects and drug tolerance hamper their application. Thus, it is of vital practical significance to explore new therapeutic targets and approaches for lung cancer. TRAIL is a promising candidate for cancer therapy as it can selectively induce apoptosis in tumor cells and effectively kill them but not normal cells (15) . Interaction between TRAIL and its cell surface receptors DR4/DR5 can result in intracellular recruitment of FADD and caspase-8/10 and formation of DISC, which can eventually trigger apoptosis of tumor cells (2) . DR1 and DR2, two receptors of TRAIL that are only expressed on normal cell membranes, are considered as decoy receptors since they have no or only part of a death domain. As a result, after binding to TRAIL, DR1 and DR2 fail to transmit apoptotic signals and hardly induce apoptosis in normal cells (16, 17) . At present, some molecular antitumor drugs targeting the TRAIL-induced apoptosis pathway have been developed, which can kill tumor cells without obvious toxicity and side effects to normal cells (18) . However, tumor cells can easily acquire resistance to TRAIL therapy (19) . Overexpression of decoy receptors and invalid mutations of TRAIL receptors together with loss of caspase-8 expression due to CASP gene methylation can cause TRAIL resistance in tumor cells (20, 21) . Additionally, NF-κB is always activated downstream in the TRAIL pathway and may more easily cause tumor cell metastasis (22) . Hence, TRAIL strategy for cancer therapy needs further improvement.
The IG20 gene was first discovered in β cells of human pancreas islets by Cunningham in 1996 (23) . It is located on human chromosome 11p11, having 5995 bp and containing 36 exons (6, 24) . By alternative splicing of exons 13L, 16, 21, 26 and 34, it can encode at least six protein isoforms: KIAA0358, IG20-SV4, IG20pa, MADD, DENN and IG20-SV2 (4). KIAA0358 and IG20-SV4 are mainly expressed in the central nervous system such as the cerebral cortex, hippocampus and spinal cord and are involved in neurotransmission (25) (26) (27) (28) and neuro-degeneration (29) . IG20pa, IG20-SV2, MADD and DENN-SV are expressed in almost all normal human tissues at low levels and participate in the TRAIL-mediated signaling pathway (4). IG20pa and IG20-SV2 have no tissue and cell specificity. MADD and DENN-SV proteins are expressed at higher levels compared to other protein isoforms (30) and are obviously increased in tumor cells and tissues (30) (31) (32) (33) , which suggests that they play important roles not only in survival of normal cells but in pathogenesis and development of tumors.
According to previous studies, continuous expression of MADD can render cells more resistant to TRAIL-induced apoptosis (30) . Phosphorylated MADD can specifically interact with TRAIL receptors to suppress cell apoptosis by means of inhibiting the cleavage of procaspase-8 (8) . Antisense abrogation of MADD expression makes tumor cells more susceptible to extracellular apoptotic stimuli such as TNF-α, TRAIL, etoposide and vinblastine (24) as well as γ-irradiation (34) . MADD expression of tumor cells markedly differs from that of normal cells (4) . Therefore, studies of the functions of MADD and regulatory mechanisms of its expression will help find novel and effective targets for TRAIL therapy against tumors.
To date, the roles of MADD in lung cancer have not been elucidated. This study mainly investigated expression of MADD in lung ADC tissues and its function in lung ADC cells. IHC analysis was used to observe MADD expression in normal and NSCLC tissues of the lungs. The results of IHC revealed that SCC and ADC tissues expressed MADD at a higher level when compared with normal lung tissues, which implies that MADD may play an important role in the pathogenesis of NSCLC. It was also found that ADC tissues had a higher MADD level than SCC tissues, indicating that ADC and SCC have different pathogenic mechanisms, and MADD may play a more vital role in ADC development. Hence, we used human lung adenocarcinoma A549 cells to further investigate the function of MADD in lung cancer. RT-PCR results showed that A549 cells expressed MADD, thus A549 cells were transfected with pEYFP-MADD plasmids or pNL-SIN-GFP-MID lentiviral vectors to increase or decrease MADD expression. MADD expression in the transfected A549 cells and cell proliferation were detected by means of western blot analysis and MTT assay, respectively. Results demonstrated that A549 cells overexpressing MADD exhibited an increased survival rate whereas silencing of MADD expression inhibited A549 cell viability. Since MADD has no obvious effect on the cell cycle (35), we applied FCM to access the influence of MADD on A549 cell apoptosis and found that MADD obviously affected the apoptosis of A549 cells. The apoptosis rate of MADD-overexpressing A549 cells was only 58.3% of that of the control cells, whereas the apoptosis rate of the MADD-silenced A549 cells was 2.8 times that of control cells, indicating that MADD strongly inhibits the apoptosis of A549 cells. These results elucidated the function of MADD in lung ADC and provides an important foundation and a promising future for improving the effects of TRAIL therapy on lung ADC by regulation and control of MADD expression and activity.
